keyword
MENU ▼
Read by QxMD icon Read
search

heart failure randomized controlled trial 2016

keyword
https://www.readbyqxmd.com/read/28330835/clinical-effectiveness-of-telemedicine-for-chronic-heart-failure-a-systematic-review-and-meta-analysis
#1
Mao-Huan Lin, Wo-Liang Yuan, Tu-Cheng Huang, Hai-Feng Zhang, Jing-Ting Mai, Jing-Feng Wang
Telemedicine interventions may be associated with reductions in hospital admission rate and mortality in patients with heart failure (HF). The present study is an updated analysis (as of June 30, 2016) of randomized controlled trials, where patients with HF underwent telemedicine care or the usual standard care. Data were extracted from 39 eligible studies for all-cause and HF-related hospital admission rate, length of stay, and mortality. The overall all-cause mortality (pooled OR=0.80, 95% CI 0.71 to 0.91, p<0...
March 22, 2017: Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research
https://www.readbyqxmd.com/read/28329380/subclinical-thyroid-dysfunction-and-cardiovascular-diseases-2016-update
#2
Carmen Floriani, Baris Gencer, Tinh-Hai Collet, Nicolas Rodondi
Subclinical thyroid dysfunction comprises subclinical hypothyroidism (SHypo), defined as elevated thyroid-stimulating hormone (TSH) by normal free thyroxine (FT4), and subclinical hyperthyroidism (SHyper) with decreased or undetectable TSH and normal FT4. Up to 10% of the elderly have SHypo, which is usually asymptomatic. Individual participant data (IPD) analyses of prospective cohort studies from the international Thyroid Studies Collaboration show that SHypo is associated with increased coronary heart disease (CHD) mortality [hazard ratio (HR) 1,58 for TSH ≥ 10 mIU/L, 95% CI 1...
February 27, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28273330/interventions-for-hereditary-haemochromatosis-an-attempted-network-meta-analysis
#3
REVIEW
Elena Buzzetti, Maria Kalafateli, Douglas Thorburn, Brian R Davidson, Emmanuel Tsochatzis, Kurinchi Selvan Gurusamy
BACKGROUND: Hereditary haemochromatosis is a genetic disorder related to proteins involved in iron transport, resulting in iron load and deposition of iron in various tissues of the body. This iron overload leads to complications including liver cirrhosis (and related complications such as liver failure and hepatocellular carcinoma), cardiac failure, cardiac arrhythmias, impotence, diabetes, arthritis, and skin pigmentation. Phlebotomy (venesection or 'blood letting') is the currently recommended treatment for hereditary haemochromatosis...
March 8, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28245343/eplerenone-for-hypertension
#4
REVIEW
Tina Sc Tam, May Hy Wu, Sarah C Masson, Matthew P Tsang, Sarah N Stabler, Angus Kinkade, Anthony Tung, Aaron M Tejani
BACKGROUND: Eplerenone is an aldosterone receptor blocker that is chemically derived from spironolactone. In Canada, it is indicated for use as adjunctive therapy to reduce mortality for heart failure patients with New York Heart Association (NYHA) class II systolic chronic heart failure and left ventricular systolic dysfunction. It is also used as adjunctive therapy for patients with heart failure following myocardial infarction. Additionally, it is indicated for the treatment of mild and moderate essential hypertension for patients who cannot be treated adequately with other agents...
February 28, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28238350/pre-cardiac-transplant-amiodarone-use-is-not-associated-with-postoperative-mortality-an-updated-meta-analysis
#5
Douglas L Jennings, William L Baker
BACKGROUND: Amiodarone remains the preferred agent for the treatment and prevention of life-threatening ventricular arrhythmias in patients with end-stage heart failure. While several reports suggest that pre-operative amiodarone exposure worsens outcomes in heart transplant recipients, other studies have failed to validate this relationship. We sought to clarify this issue by performing a meta-analysis of the available literature surrounding this topic. METHODS: We searched Medline, SCOPUS and the Cochrane Central Register of Controlled Trials through December 15th 2016, as well as proceedings from related conferences over the prior 3years...
February 14, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28176521/implantable-cardioverter-defibrillators-for-primary-prevention-in-patients-with-nonischemic-cardiomyopathy-a-systematic-review-and-meta-analysis
#6
Tamer Akel, James Lafferty
INTRODUCTION: Implantable cardioverter defibrillators (ICDs) have proved their benefit in exerting favorable outcomes on survival in selected patients with cardiomyopathy. Although previous meta-analyses have shown benefit for their use in primary prevention, the evidence is less robust for patients with NICM in comparison to patients with CAD. In this meta-analysis we evaluated the ability of ICD therapy in reducing all-cause mortality and sudden cardiac Death (SCD) in patients with NICM...
February 8, 2017: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/28166237/no-benefits-of-statins-for-sudden-cardiac-death-prevention-in-patients-with-heart-failure-and-reduced-ejection-fraction-a-meta-analysis-of-randomized-controlled-trials
#7
Muaamar Al-Gobari, Hai-Ha Le, Mor Fall, François Gueyffier, Bernard Burnand
BACKGROUND AND OBJECTIVES: Statins showed mixed results in heart failure (HF) patients. The benefits in major HF outcomes, including all-cause mortality and sudden cardiac death (SCD), have always been discordant across systematic reviews and meta-analyses. We intended to systematically identify and appraise the available evidence that evaluated the effectiveness of statins in clinical outcomes for HF patients. DESIGN: Systematic review and meta-analysis. DATA SOURCES: We searched, until April 28, 2016: Medline, Embase, ISI Web of Science and EBM reviews (Cochrane DSR, ACP journal club, DARE, CCTR, CMR, HTA, and NHSEED), checked clinicaltrials...
2017: PloS One
https://www.readbyqxmd.com/read/28153104/outcomes-of-intensive-blood-pressure-lowering-in-older-hypertensive-patients
#8
Chirag Bavishi, Sripal Bangalore, Franz H Messerli
BACKGROUND: The 2014 Eighth Joint National Committee panel recommended a therapeutic target of systolic blood pressure (BP) <150 mm Hg in patients ≥60 years of age, a departure from prior recommendation of <140 mm Hg. OBJECTIVES: This study assessed the efficacy and safety of intensive BP-lowering strategies in older (age ≥65 years) hypertensive patients. METHODS: The MEDLINE, Scopus, EMBASE, and Cochrane databases were searched for all relevant randomized controlled trials from 1965 through July 1, 2016...
February 7, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28129469/implantable-cardioverter-defibrillators-for-primary-prevention-in-patients-with-nonischemic-cardiomyopathy-a-systematic-review-and-meta-analysis
#9
Tamer Akel, James Lafferty
BACKGROUND: Implantable cardioverter defibrillators (ICDs) have proved their benefit in exerting favorable outcomes on survival in selected patients with cardiomyopathy. Although previous meta-analyses have shown benefit for their use in primary prevention, the evidence is less robust for patients with NICM in comparison to patients with CAD. OBJECTIVES: To evaluate the ability of ICD therapy in reducing all-cause mortality and sudden cardiac death (SCD) in patients with NICM...
January 27, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28107561/beta-blockers-for-hypertension
#10
REVIEW
Charles S Wiysonge, Hazel A Bradley, Jimmy Volmink, Bongani M Mayosi, Lionel H Opie
BACKGROUND: Beta-blockers refer to a mixed group of drugs with diverse pharmacodynamic and pharmacokinetic properties. They have shown long-term beneficial effects on mortality and cardiovascular disease (CVD) when used in people with heart failure or acute myocardial infarction. Beta-blockers were thought to have similar beneficial effects when used as first-line therapy for hypertension. However, the benefit of beta-blockers as first-line therapy for hypertension without compelling indications is controversial...
January 20, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28104622/renin-angiotensin-system-inhibitors-for-patients-with-stable-coronary-artery-disease-without-heart-failure-systematic-review-and-meta-analysis-of-randomized-trials
#11
Sripal Bangalore, Robert Fakheri, Simon Wandel, Bora Toklu, Jasmin Wandel, Franz H Messerli
OBJECTIVE:  To critically evaluate the efficacy of renin angiotensin system inhibitors (RASi) in patients with coronary artery disease without heart failure, compared with active controls or placebo. DESIGN:  Meta-analysis of randomized trials. DATA SOURCES:  PubMed, EMBASE, and CENTRAL databases until 1 May 2016. ELIGIBILITY CRITERIA FOR SELECTING STUDIES:  Randomized trials of RASi versus placebo or active controls in patients with stable coronary artery disease without heart failure (defined as left ventricular ejection fraction ≥40% or without clinical heart failure)...
January 19, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28100921/clinical-significance-of-cardiometabolic-memory-a-systematic-review-of-randomized-controlled-trials
#12
REVIEW
Hiroshi Itoh, Isao Kurihara, Kazutoshi Miyashita, Masami Tanaka
'Cardiometabolic memory' has been proposed based on clinical evidence to explain how, even after the cessation of a clinical trial, the superiority of one treatment over the outcome persists. To understand the cardiometabolic memory phenomenon, we performed a systematic review of randomized controlled trials (RCTs) using PubMed in August 2016. The search terms 'randomized controlled trial', 'post-trial follow-up' and 'diabetes, hypertension or dyslipidemia' were used, and articles published after the year 2000 were searched...
January 19, 2017: Hypertension Research: Official Journal of the Japanese Society of Hypertension
https://www.readbyqxmd.com/read/28097882/antidiabetic-agents-and-cardiovascular-outcomes-in-patients-with-heart-diseases
#13
Judy W M Cheng, Hisham A Badreldin, Dhiren K Patel, Snehal H Bhatt
INTRODUCTION: This article reviews evidence of the benefits and risk of antidiabetic agents in cardiovascular (CV) outcomes, with a focus on medications approved by the FDA since 2008. STUDY SELECTION: Peer-reviewed articles were identified from MEDLINE and Current Content databases (both 1966 to 1 October 2016) using the search terms insulin, metformin, rosiglitazone, pioglitazone, glyburide, glipizide, glimepiride, acarbose, miglitol, albiglutide, exenatide, liraglutide, lixisenatide, dulaglutide, pramlintide, meglitinide, alogliptin, linagliptin, saxagliptin, sitagliptin, canagliflozin, dapagliflozin, empagliflozin, colesevalam, bromocriptine, mortality, myocardial infarction (MI), heart failure (HF), and stroke...
February 15, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28075489/cough-augmentation-techniques-for-extubation-or-weaning-critically-ill-patients-from-mechanical-ventilation
#14
REVIEW
Louise Rose, Neill Kj Adhikari, David Leasa, Dean A Fergusson, Douglas McKim
BACKGROUND: There are various reasons why weaning and extubation failure occur, but ineffective cough and secretion retention can play a significant role. Cough augmentation techniques, such as lung volume recruitment or manually- and mechanically-assisted cough, are used to prevent and manage respiratory complications associated with chronic conditions, particularly neuromuscular disease, and may improve short- and long-term outcomes for people with acute respiratory failure. However, the role of cough augmentation to facilitate extubation and prevent post-extubation respiratory failure is unclear...
January 11, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27999139/pioglitazone-for-secondary-stroke-prevention-a-systematic-review-and-meta-analysis
#15
Meng Lee, Jeffrey L Saver, Hung-Wei Liao, Chun-Hsien Lin, Bruce Ovbiagele
BACKGROUND AND PURPOSE: Pioglitazone reduced major vascular events after ischemic stroke in a recent randomized controlled trial. The purpose of this study was to conduct a meta-analysis of randomized controlled trials to evaluate the effect of pioglitazone therapy in reducing the risk of recurrent stroke in stroke patients. METHODS: Pubmed, EMBASE, Medline, and Cochrane Central Register of Controlled Trials from 1966 to March 2016 were searched to identify relevant studies...
February 2017: Stroke; a Journal of Cerebral Circulation
https://www.readbyqxmd.com/read/27955682/health-effectiveness-and-cost-effectiveness-of-telehealthcare-for-heart-failure-study-protocol-for-a-randomized-controlled-trial
#16
Simon Lebech Cichosz, Lars Holger Ehlers, Ole Hejlesen
BACKGROUND: Several heart failure studies have shown promising results for implementing telehealthcare. These studies have led to clinical and political interest in telehealthcare as a way to improve heart failure outcomes and lower costs. However, there is a need for large-scale clinical trials with cost-effectiveness assessments. METHODS/DESIGN: The present study is known as the TeleCare North Heart Failure Trial in Denmark. We are studying the health effectiveness and cost-effectiveness of a telehealth (Telekit) solution compared with usual care for patients with heart failure...
December 12, 2016: Trials
https://www.readbyqxmd.com/read/27866027/cardiovascular-outcomes-with-sodium-glucose-cotransporter-2-inhibitors-in-patients-with-type-ii-diabetes-mellitus-a-meta-analysis-of-placebo-controlled-randomized-trials
#17
Marwan Saad, Ahmed N Mahmoud, Islam Y Elgendy, Ahmed Abuzaid, Amr F Barakat, Akram Y Elgendy, Mohammad Al-Ani, Amgad Mentias, Ramez Nairooz, Anthony A Bavry, Debabrata Mukherjee
BACKGROUND: The impact of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on cardiovascular outcomes in patients with type II diabetes mellitus (DM) is not well established. METHODS: We searched electronic databases from inception through July 2016 for randomized, placebo-controlled trials, involving SGLT-2 inhibitors. Fixed-effects summary odds ratios (OR) were constructed using Peto model. RESULTS: Eighty-one trials with a total of 37,195 patients were included...
February 1, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/27827525/the-clinical-effectiveness-of-telemedicine-for-chronic-heart-failure-a-systematic-review-and-meta-analysis
#18
Mao H Lin, Wo L Yuan, Tu C Huang, Hai F Zhang, Jing T Mai, Jing F Wang
INTRODUCTION: Telemedicine interventions had been found to effectively reduce all-cause mortality and hospital admission rate of the patients with heart failure (HF). This study aims to update the clinical benefit of telemedicine for HF. EVIDENCE ACQUISITION: Literature databases (updated to June 30, 2016) were searched for randomized controlled trials for HF patients, in which the participants were randomized into telemedicine group (tele-transmission, telephone-supported care, and implantable monitoring) or the usual standard care group...
November 9, 2016: Minerva Medica
https://www.readbyqxmd.com/read/27764523/benzodiazepines-for-the-relief-of-breathlessness-in-advanced-malignant-and-non-malignant-diseases-in-adults
#19
REVIEW
Steffen T Simon, Irene J Higginson, Sara Booth, Richard Harding, Vera Weingärtner, Claudia Bausewein
BACKGROUND: This is an updated version of the original Cochrane review published in Issue 1, 2010, on 'Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults'. Breathlessness is one of the most common symptoms experienced in the advanced stages of malignant and non-malignant disease. Benzodiazepines are widely used for the relief of breathlessness in advanced diseases and are regularly recommended in the literature. At the time of the previously published Cochrane review, there was no evidence for a beneficial effect of benzodiazepines for the relief of breathlessness in people with advanced cancer and chronic obstructive pulmonary disease (COPD)...
October 20, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27754167/sy-12-3-are-ras-inhibitors-necessary-for-all-patients-with-diabetes-and-chronic-kidney-disease
#20
Shokei Kim-Mitsuyama
There is accumulating evidence that RAS inhibitors not only reduce blood pressure, but also exert pleiotropic effects, including a renoprotective effect, amelioration of insulin resistance, reduction in onset of diabetes, and suppression of cardiovascular remodelling,. However, the definite benefit of RAS inhibition in treatment of hypertension with CKD or DM is not conclusive. We previously performed the OlmeSartan and Calcium Antagonists Randomized (OSCAR) study comparing the preventive effect of high-dose ARB therapy versus ARB plus CCB combination therapy on cardiovascular morbidity and mortality in 1164 Japanese elderly hypertensive patients with baseline type 2 diabetes and/or CVD (Am J Med (2012))...
September 2016: Journal of Hypertension
keyword
keyword
89424
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"